110 completed, 59 recruiting, 43 unknown, 19 active not recruiting. 269 Phase 3, 42 Phase 2.
Follow Injections: new trials by email Literature Review of Injections trials Research Report on Injections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study in Participants With Relapsed or Refractory Multiple Myeloma for QLS4131 QLS4131, Pomalidomide Capsules, Bortezomib for Injection - Relapsed or Refractory Multiple Myeloma | Phase 3 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 300 | 2026-12-30 | 2026-11-12 |
| Study of Efficacy and Safety of FRSW107 in Pediatric Patients With Severe Hemophilia A FRSW107 - Severe Hemophilia A | Phase 3 | Not yet recruiting | Hangzhou Gensciences Biopharmaceutical Co., Ltd. | 76 | 2026-12-25 | 2024-06-20 |
| A Study of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overexpressing Non-squamous Non-small Cell Lung Cancer SHR-A1811 Injection, Adebrelimab Injection, Tislelizumab Injection - Non Small Cell Lung Cancer | Phase 3 | Not yet recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 436 | 2026-12-01 | 2026-10-26 |
| Indigotindisulfonate Sodium Injection, USP as an Aid in the Determination of Ureteral Patency in Pediatric Patients Indigotindisulfonate sodium 0.8% injection - Ureter Injury | Phase 3 | Not yet recruiting | Prove pharm | 18 | 2026-12-01 | 2026-10-16 |
| Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer EG-007, Pembrolizumab 100 mg/ 4 ml (25 mg/ml) Injection, Lenvatinib Capsules - Advanced Endometrial Cancer | Phase 3 | Not yet recruiting | Evergreen Therapeutics, Inc. | 450 | 2026-12-01 | 2025-12-08 |
| PRP Versus NP Injections for Chronic Discogenic Low Back Pain Platelet-Rich Plasma (PRP) Injection, Nucleus Pulposus (NP) Injection - Discogenic Low Back Pain | Phase 2 / Phase 3 | Not yet recruiting | Walter Reed National Military Medical Center | 60 | 2026-12-01 | 2026-11-02 |
| Recombinant Human Prourokinase for Acute Ischemic Stroke in the Extended Window Selected by CT-Based Artificial Intelligence Recombinant Human Prourokinase for Injection (rhPro-UK), Matching Placebo for Recombinant Human Prourokinase - Acute Ischemic Stroke | Phase 3 | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 826 | 2026-12-01 | 2026-10-28 |
| A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NEC LBL-024 for Injection, Etoposide injection, Cisplatin injection - Advanced Extrapulmonary Neuroendocrine Carcinoma | Phase 3 | Not yet recruiting | Nanjing Leads Biolabs Co.,Ltd | 280 | 2026-11-16 | 2026-10-19 |
| RC118 Combined With RC148 as First-Line Treatment for Claudin 18.2-Positive, HER2-Negative Advanced G/GEJ Adenocarcinoma RC118(Dose 1) plus RC148(Dose 1), RC118(Dose 1) plus RC148(Dose 2), RC118(Dose 2) plus RC148(Dose 1) - Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | Phase 2 / Phase 3 | Not yet recruiting | RemeGen Co., Ltd. | 680 | 2026-11-01 | 2026-11-13 |
| ZG005 Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy for Advanced Hepatocellular ZG005 for Injection, Bevacizumab ( Avastin), Sintilimab - Hepatocellular Carcinoma | Phase 3 | Recruiting | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 600 | 2026-10-20 | 2026-11-16 |
| A Clinical Trial Evaluating the Efficacy and Safety of Local Infiltration of RF16001 for Injection for Analgesia After Total Hip Arthroplasty in China RF16001 for injection, Ropivacaine hydrochloride injection, 0.9% sodium chloride injection - Pain After Abdominal Surgery | Phase 3 | Enrolling by invitation | The Third Xiangya Hospital of Central South University | 300 | 2026-10-10 | 2026-10-14 |
| Phase III Study of RC148 Plus Chemotherapy Versus Tislelizumab Plus Chemotherapy as First-Line Treatment for Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations RC148 Injection plus Pemetrexed Disodium for Injection and Carboplatin Injection, Tislelizumab Injection plus Pemetrexed Disodium for Injection and Carboplatin Injection - Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations | Phase 3 | Recruiting | RemeGen Co., Ltd. | 540 | 2026-10-10 | 2026-11-12 |
| Intravenous Recombinant Human Prourokinase for Acute Medium Vessel Occlusion 4.5-24 Hours After Ischemic Stroke Recombinant Human Prourokinase for Injection (rhPro-UK), Standard medical treatment (SMT) - Acute Ischemic Stroke | Phase 3 | Recruiting | The First Affiliated Hospital of Anhui Medical University | 616 | 2026-10-06 | 2026-10-07 |
| ZG005 Plus Etoposide and Cisplatin vs. Etoposide and Cisplatin as First-Line Treatment for Advanced Neuroendocrine Carcinoma ZG005 for Injection, Etoposide Injection, Cisplatin Injection - Neuroendocrine Carcinomas (NEC) | Phase 3 | Not yet recruiting | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 440 | 2026-10-01 | 2026-09-22 |
| HRS-4642 Combined With Antitumor Agents for the Treatment of Perioperative Pancreatic Cancer HRS -4642 + SHR-1316+ Gemcitabine Hydrochloride for Injection+Paclitaxel for Injection, HRS -4642 + Gemcitabine Hydrochloride for Injection+Paclitaxel for Injection, Gemcitabine Hydrochloride for Injection+Paclitaxel for Injection - Systemic Treatment-naïve Pancreatic Cancer | Phase 3 | Not yet recruiting | Shanghai Hengrui Pharmaceutical Co., Ltd. | 825 | 2026-10-01 | 2026-10-28 |
| A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME). 4D-150 IVT (3x10^10 vg), EYELEA ® (aflibercept) Injection 2 mg (0.05mL) - Diabetic Macular Edema (DME) | Phase 3 | Recruiting | 4D Molecular Therapeutics | 514 | 2026-09-18 | 2026-11-10 |
| A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer Trastuzumab Rezetecan for Injection, Adebrelimab Injection, Capecitabine tablets - Triple Negative Breast Cancer | Phase 3 | Recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 1000 | 2026-09-02 | 2026-09-09 |
| A Study of Injectable BLB101 and Blincyto® in Adult Participants With R/R CD19+ B-ALL BLB101 for Injection, Blinatumomab for Injection - Precursor B-cell Acute Lymphoblastic Leukemia | Phase 3 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 212 | 2026-08-09 | 2026-07-23 |
| A Study of HS-20093 in Patients With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) HS-20093 for Injection, Irinotecan; Paclitaxel; Docetaxel - Esophageal Squamous Cell Carcinoma (ESCC) | Phase 3 | Not yet recruiting | Hansoh BioMedical R&D Company | 494 | 2026-07-31 | 2026-06-02 |
| Neoadjuvant and Adjuvant Therapy Studies of Sintilimab Combined With Chemotherapy With or Without Ipilimumab N01 in Resectable Gastric/Gastroesophageal Junction Adenocarcinoma tegafur, Gimeracil and Oteracil Potassium Capsules, Sintilimab Placebo, Sintilimab - Resectable Gastric/Gastroesophageal Junction Adenocarcinoma | Phase 2 / Phase 3 | Recruiting | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | 720 | 2026-07-31 | 2026-08-14 |
Showing 20 of 269. Sign in to see all of them.
Breast Neoplasms (12) · Ischemic Stroke (8) · Carcinoma, Non-Small-Cell Lung (7) · Hemophilia A (7) · Agnosia (6) · COVID-19 (6) · Leukemia, Myeloid, Acute (6) · Carcinoma, Hepatocellular (5) · Infertility (5) · Pain (5) · Pain, Postoperative (5) · Prostatic Neoplasms (5) · Triple Negative Breast Neoplasms (5) · Infertility, Female (4) · Lymphoma, Large B-Cell, Diffuse (4)
Suzhou Suncadia Biopharmaceuticals Co., Ltd. (8) · Jiangsu HengRui Medicine Co., Ltd. (5) · Beijing Tiantan Hospital (4) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (4) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (4) · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. (4) · Chongqing Claruvis Pharmaceutical Co., Ltd. (4) · Eisai Inc. (4) · Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd (4) · Sanofi (4) · 4D Molecular Therapeutics (3) · Hoffmann-La Roche (3) · Lanzhou Institute of Biological Products Co., Ltd (3) · RemeGen Co., Ltd. (3) · Shanghai Junshi Bioscience Co., Ltd. (3)
China (125) · United States (63) · France (26) · Germany (24) · Canada (23) · Italy (20) · Spain (20) · United Kingdom (20) · Australia (15) · Poland (15) · Belgium (14) · Brazil (11) · Hungary (11) · Netherlands (11) · Austria (10)
Doug Green (2) · James Jones, MD, PharmD (2) · Jiong Wu (2) · Li Zhang, MD (2) · Renchi Yang (2) · Rui Avelar, MD (2) · Yan Wu (2) · Yang Yi, MD (2) · Abbot R Laptook, MD (1) · Abdelrahman A Abdelalim, MD (1) · Abhik Das, PhD (1) · Aiping Zhou, MD (1)
PMID 21482570, PMID 23357290, PMID 25487791, PMID 26702925, PMID 30597021, PMID 33438477, PMID 34922058, PMID 10933646, PMID 11981766, PMID 12049862, PMID 12091661, PMID 12540794, PMID 17585221, PMID 17855671, PMID 18294998, PMID 18444850, PMID 18641105, PMID 19348685, PMID 19530976, PMID 19850694, PMID 20610825, PMID 20850390, PMID 21482566, PMID 21482568, PMID 21487286, PMID 22127693, PMID 22435369, PMID 22564837, PMID 23224215, PMID 23861303, PMID 24292991, PMID 24324944, PMID 24531850, PMID 24727841, PMID 25005327, PMID 25187512, PMID 25503156, PMID 25517348, PMID 25619263, PMID 25671797, PMID 25671798, PMID 25677596, PMID 25708147, PMID 25727857, PMID 25882376, PMID 25882510, PMID 26060065, PMID 26281972, PMID 26314234, PMID 26361207
2019 (3), 2017 (2), 2023 (2), 2014 (1), 2015 (1), 2016 (1), 2018 (1), 2025 (1), U10CA180886 (1), U10CA180888 (1), U10HD021364 (1), U10HD021373 (1), U10HD021385 (1), U10HD027851 (1), U10HD027853 (1)